SAN DIEGO & TOKYO--(BUSINESS WIRE)--April 20, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News) announced today approval to begin an investigator-initiated safety and feasibility study in Japan using adult adipose (fat) derived stem and regenerative cells for breast reconstruction. This study has been approved by the Institutional Review Board and the first patient has been enrolled and is scheduled to be treated in May.
